p.350 抽出テキスト

5) Hale M, Wild J, Reddy J, et al. Naldemedine versus placebo for opioid‒induced constipation

(COMPOSE‒1 and COMPOSE‒2): two multicentre, phase 3, double‒blind, randomised, parallel‒group trials. Lancet Gastroenterol Hepatol 2017; 2: 555‒64 6) Katakami N, Oda K, Tauchi K, et al. Phase IIb, randomized, double‒blind, placebo‒controlled study of naldemedine for the treatment of opioid‒induced constipation in patients with cancer. J Clin Oncol 2017; 35: 1921‒8 7) Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double‒blind placebo‒ controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid‒induced constipation in patients with chronic noncancer pain. Pain Med 2017; 18: 2350‒60 8) Webster LR, Brewer RP, Lichtlen P, et al. Efficacy of lubiprostone for the treatment of opioid‒ induced constipation, analyzed by opioid class. Pain Med 2018; 19: 1195‒205 9) Spierings ELH, Drossman DA, Cryer B, et al. Efficacy and safety of lubiprostone in patients with opioid‒induced constipation: phase 3 study results and pooled analysis of the effect of concomitant methadone use on clinical outcomes. Pain Med 2018; 19: 1184‒94 10) Webster LR, Nalamachu S, Morlion B, et al. Long‒term use of naldemedine in the treatment of opioid‒induced constipation in patients with chronic noncancer pain: a randomized, double‒blind, placebo‒controlled phase 3 study. Pain 2018; 159: 987‒94 11) Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies of nalde-

medine in patients with opioid‒induced constipation and cancer. J Clin Oncol 2017; 35: 3859‒66.

【参考文献】a) Crockett SD, Greer KB, Heidelbaugh JJ, et al.; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Medical Management of Opioid‒Induced Constipation. Gastroenterology 2019; 156: 218‒26 b) Müller‒Lissner S, Bassotti G, Coffin B, et al. Opioid‒induced constipation and bowel dysfunction: a clinical guideline. Pain Med 2017; 18: 1837‒63 c) Candy B, Jones L, Vickerstaff V, et al. Mu‒opioid antagonists for opioid‒induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database Syst Rev 2018; 6: CD006332 d) Rossi M, Casale G, Badiali D, et al. Opioid‒induced bowel dysfunction: suggestions from a

multidisciplinary expert Board. Support Care Cancer 2019; 27: 4083‒90 III章推奨